It is essential to highlight that earlier studies (4) assessed a median OS of 16.9 (95% confidence interval [CI] 14.9-18.8) months in patients with unresectable HCC treated with a combination of TACE, TKI, and PD-1 inhibitors. Here, PDCD1 is linked to hepatocellular carcinoma.